Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study

Jason Gotlib, MD MS, Deepti H. Radia, MRCPI, FRCPath, Tracy I. George, MD, William A Robinson, MD PhD, Albert T. Quiery, MD, Mark W. Drummond, PhD FRCPath, Prithviraj Bose, MD, Elizabeth O. Hexner, MD, Elliott F. Winton, MD, Hans-Peter Horny, Prof, Dr, Meera Tugnait, PhD, Oleg Schmidt-Kittler, PhD, Erica K. Evans, PhD, Hui-Min Lin, PhD, Brenton G. Mar, MD PhD, Michael W. Deininger, MD PhD, Daniel J. DeAngelo, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137413

Published: 2020

Journal Articles

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Tim H Brümmendorf, MD, Jorge E. Cortes, MD, Dragana Milojkovic, Carlo Gambacorti-Passerini, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Philipp D le Coutre, MD, Valentín Garcia-Gutiérrez, MD PhD, Charles Chuah, MD, Vamsi Kota, MD, Jeffrey H. Lipton, MD PhD, Philippe Rousselot, MDPhD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Rafael Hurtado Monroy, MD, Eric Leip, Simon Purcell, Anne Yver, PharmD, Andrea Viqueira, MD, Michael W. Deininger, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-137393

Published: 2020

Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135883

Published: 2020

Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-133922

Published: 2020

Journal Articles

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Blood (2020) 136 (Supplement 1): 47–50.

https://doi.org/10.1182/blood-2020-139677

Published: 2020

Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139847

Published: 2020

Journal Articles

Drug-Free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction By Pretreatment with Gemcitabine

Jiawei Wang, Lian Li, PhD, Jiyuan Yang, PhD, Phillip M. Clair, MS, Martha Glenn, MD, Deborah M. Stephens, D. Christopher Radford, PhDCandidate, Ken M. Kosak, Michael W. Deininger, MD PhD, Paul J Shami, MD, Jindřich Kopeček, PhD

Blood (2018) 132 (Supplement 1): 4426.

https://doi.org/10.1182/blood-2018-99-112001

Published: 2018

Journal Articles

Disease Characteristics and Treatment of Adult Langerhans Cell Histiocytosis: A Single Center Experience

Jason Signorelli, MD PhD MBA, Sowmya Ravulapati, MBBS, Jay L Patel, MD, Michael W. Deininger, MD PhD, Srinivas K. Tantravahi, MBBS

Blood (2018) 132 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2018-99-120290

Published: 2018

Journal Articles

Pregnancy Outcomes in Patients Treated with Bosutinib

Jorge E. Cortes, MD, Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Elisabetta Abruzzese, Liza DeAnnuntis, Tim H Brümmendorf, MD

Blood (2018) 132 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2018-99-110547

Published: 2018

Journal Articles

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial

Michael W. Deininger, MD PhD, Vamsi Kota, MBBS, Jeff H. Lipton, MD PhD, Dragana Milojkovic, MBBS, PhD, Valentín García Gutiérrez, PhD, Eric Leip, PhD, Sonja Nick, MSc, Andreas Hochhaus, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Tim H. Brummendorf, MD

Blood (2018) 132 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2018-99-110798

Published: 2018

Journal Articles

SIRT5 As a Therapeutic Target in Acute Myeloid Leukemia

Dongqing Yan, Anthony D. Pomicter, MS, William L. Heaton, MS, Clint C. Mason, PhD, Jonathan Ahmann, BS, Anna Senina, MS, Anca Franzini, PhD, Brayden Halverson, Hein Than, MD FRCPath, MRCP, Phillip M. Clair, MS, Jamshid S Khorashad, MD PhD, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 907.

https://doi.org/10.1182/blood-2018-99-115468

Published: 2018

Journal Articles

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Delphine Rea, MD, Fabian Lang, MD, Dong-Wook Kim, MD PhD, Jorge E. Cortes, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Hironobu Minami, MD PhD, Massimo Breccia, MD, Daniel J. Deangelo, MD, Andreas Hochhaus, MD, Moshe Talpaz, MD, Yeow Tee Goh, MBBS,MD, Philipp le Coutre, MD, Michael W. Deininger, MD PhD, Gabriel Etienne, MD PhD, Manu Sondhi, MD PhD, Kaushal Mishra, PhD, Paola Aimone, MD, Janet Ng-Sikorski, PhD, Michael J. Mauro, MD

Blood (2018) 132 (Supplement 1): 792.

https://doi.org/10.1182/blood-2018-99-113609

Published: 2018

Journal Articles

Molecular Alterations in Chronic Myelomonocytic Leukemia Monocytes: Transcriptional and Methylation Profiling

Anca Franzini, PhD, Jamshid S Khorashad, MD PhD, Hein Than, MD FRCPath, MRCP, Anthony D. Pomicter, MS, Dongqing Yan, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 3889.

https://doi.org/10.1182/blood-2018-99-115077

Published: 2018

Journal Articles

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Kim-Hien Dao, DO,PhD, Robert H. Collins, MD, Jorge E. Cortes, MD, Michael W. Deininger, MD PhD, Brian J. Druker, MD, Jason R. Gotlib, MDMS, Tara Alyson Macey, PhD, Stephen T Oh, MD PhD, Jeffrey W. Tyner, PhD, Elliott F. Winton, MD

Blood (2018) 132 (Supplement 1): 350.

https://doi.org/10.1182/blood-2018-99-119476

Published: 2018

Journal Articles

Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance

Ami B. Patel, MD, Anthony D. Pomicter, MS, Dongqing Yan, Anna M. Eiring, PhD, Anca Franzini, PhD, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 2641.

https://doi.org/10.1182/blood-2018-99-117276

Published: 2018

Journal Articles

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)

Jason R. Gotlib, MDMS, Deepti Radia, MD, Daniel J. DeAngelo, MD, Prithviraj Bose, MD, Mark W Drummond, PhDMD, Elizabeth O. Hexner, MDMS, William A Robinson, MD PhD, Maureen G. Conlan, MD, Ronny G. Oren, MS, Hongliang Shi, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 351.

https://doi.org/10.1182/blood-2018-99-112017

Published: 2018

Journal Articles

Synergistic Effect of Imatinib and Ruxolitinib in a Patient with JAK2 V617F positive Myelofibrosis and Concomitant BCR-ABL1 positive Chronic Myeloid Leukemia

Srinivas K. Tantravahi, MBBS, Soo Jin Kim, MS, Jeffrey A Gilreath, PharmD, Anthony D. Pomicter, MS, Tsewang Tashi, MD, Michael W. Deininger, MD PhD, Josef T. Prchal, MD

Blood (2018) 132 (Supplement 1): 5482.

https://doi.org/10.1182/blood-2018-99-119745

Published: 2018

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

Journal Articles

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Blood (2018) 132 (Supplement 1): 559.

https://doi.org/10.1182/blood-2018-99-118494

Published: 2018

Journal Articles

Comorbidities Are Major Drivers of Overall Survival of Chronic Myelomonocytic Leukemia

Tyson Broadbent, MD, Srinivas K. Tantravahi, MBBS, Sowmya Ravulapati, MBBS, Morgan Ward, Alexandra Asay, Ananth Peddinti, MS, Isaac Kunz, MS, Paul J Shami, MD, Tibor Kovacsovics, MD, Samir Courdy, MBA, Ken Boucher, PhD, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 5521.

https://doi.org/10.1182/blood-2018-99-119339

Published: 2018

NARROW

Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Drug-Free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction By Pretreatment with Gemcitabine

Disease Characteristics and Treatment of Adult Langerhans Cell Histiocytosis: A Single Center Experience

Pregnancy Outcomes in Patients Treated with Bosutinib

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial

SIRT5 As a Therapeutic Target in Acute Myeloid Leukemia

Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial

Molecular Alterations in Chronic Myelomonocytic Leukemia Monocytes: Transcriptional and Methylation Profiling

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)

Synergistic Effect of Imatinib and Ruxolitinib in a Patient with JAK2 V617F positive Myelofibrosis and Concomitant BCR-ABL1 positive Chronic Myeloid Leukemia

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Comorbidities Are Major Drivers of Overall Survival of Chronic Myelomonocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only